Scott Auerbach MD 
Bivairudin is associated with lower mortality AND is cost effective when compared to heparin in pediaatric VAD management. Congrats @jen_conway1! @ACTION4HF @phts #LVAD #pedshf https://www.jhltonline.org/article/S1053-2498(22)02172-6/fulltext
Cost-effectiveness of bivalirudin in pediatric ventricular assist devices
Despite recent data suggesting improved outcomes with bivalirudin vs heparin in pediatric Ventricular assist devices (VAD), higher costs remain a barrier. This study quantified trends in bivalirudin use and compared outcomes, resource utilization, and cost-effectiveness associated with bivalirudin vs heparin.